secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001193125-25-125484
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics shareholders approve reverse stock split at 1:10-1:30 ratio
--------------------------------------------------------------------------------

- Elected directors William Ringo (8.9M for) and John Celebi (9.2M for) to three-year terms.
- Ratified Deloitte & Touche as independent auditor for FY2025: 15.8M for, 369.9K against.
- Approved reverse stock split authorization (ratio 1:10 to 1:30) at board discretion; 14.7M for, 1.6M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525125484/0001193125-25-125484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525125484/d13190d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-125484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer